This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Learn about retirement plans that might be better than a 401k. Enhance your retirement strategy with informed choices.
27,827 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
JPMorgan downgraded Wix.com to Underweight and cut its price target to $91, citing slower core growth and volatile ma...
New data shows around 22 million teenagers are earning money online through games, resale, and in-game marketplaces, ...
A new collaboration between TSMC and Winbond intends to ease DRAM bottlenecks for AI workloads. It’s framed by analys...
Unanimity in board votes can mask risk. A fresh comparison to avalanche safety training shows why dissent matters for...
Netflix has staged a comeback that rewards patient investors, but the last year also exposed two distinct paths for t...
Samsung outperformed Nvidia on operating profit in the latest quarter, even as market jitters hit the chip sector. Ji...
With gas prices hovering near $4 per gallon, diners are tightening belts, and restaurant sales are cooling. Analysts ...
SpaceX plans to raise $75 billion at $135 per share, listing SPCX on Nasdaq this Friday. A 30% retail tranche and tou...
The U.S. government is on a heavy borrowing pace in fiscal 2026, with monthly borrowing around $155 billion and inter...
Gas prices keep rising as markets weigh supply risks, yet there is scant evidence that major oil companies will ramp ...
A wave of token launches has stumbled, pushing traders toward tokenized stocks. Exchanges are racing to monetize reta...